The Covid-19 is a highly contagious disease which becomes a serious global health concern. The residents living in areas with high population density, such as big or metropolitan cities, have a higher probability to come into close contact with others and consequently any contagious disease is expected to spread rapidly in dense areas. However, recently, after analyzing Covid-19 cases in the USA researchers at the

With the exploding power consumption in private households and increasing environmental and regulatory restraints, the need to improve the overall efficiency of electrical networks has never been greater. That being said, the most efficient way to minimize the power consumption is by voluntary mitigation of home electric energy consumption, based on energy-awareness and automatic or manual reduction of standby power of idling home appliances. Deploying bi-directional smart meters and home energy management (HEM) agents that provision real-time usage monitoring and remote control, will enable HEM in “smart households.” Furthermore, the traditionally inelastic demand curve has began to change, and these emerging HEM technologies enable consumers (industrial to residential) to respond to the energy market behavior to reduce their consumption at peak prices, to supply reserves on a as-needed basis, and to reduce demand on the electric grid. Because the development of smart grid-related activities has resulted in an increased interest in demand response (DR) and demand side management (DSM) programs, this paper presents some popular DR and DSM initiatives that include planning, implementation and evaluation techniques for reducing energy consumption and peak electricity demand. The paper then focuses on reviewing and distinguishing the various state-of-the-art HEM control and networking technologies, and outlines directions for promoting the shift towards a society with low energy demand and low greenhouse gas emissions. The paper also surveys the existing software and hardware tools, platforms, and test beds for evaluating the performance of the information and communications technologies that are at the core of future smart grids. It is envisioned that this paper will inspire future research and design efforts in developing standardized and user-friendly smart energy monitoring systems that are suitable for wide scale deployment in homes.

No abstract

Abstract. Microfluidics-based biochips are soon expected to revolutionize biosensing, clinical diagnostics and drug discovery. Robust off-line and on-line test techniques are required to ensure system dependability as these biochips are deployed for safety-critical applications. Due to the underlying mixed-technology and mixed-energy domains, biochips exhibit unique failure mechanisms and defects. We first relate some realistic defects to fault models and observable errors. We next set up an experiment to evaluate the manifestations of electrode-short faults. Motivated by the experimental results, we present a testing and diagnosis methodology to detect catastrophic faults and locate faulty regions. The proposed method is evaluated using a biochip performing real-life multiplexed bioassays.

Objectives To assess the effect of rituximab (RTX) on the lung function parameters in SSc interstitial lung disease (SSc-ILD) patients. Methods PubMed and Embase were searched to identify studies on SSc-ILD treated with RTX, confined to a predefined inclusion and exclusion criteria. A systematic review and meta-analysis were performed on the included studies on changes in forced vital capacity (FVC) and diffusion capacity of carbon monoxide (DLCO) from baseline to 6 and 12 months of follow-up. Results A total of 20 studies (2 randomized controlled trials, 6 prospective studies, 5 retrospective studies and 7 conference abstracts) were included (n = 575). RTX improved FVC from baseline by 4.49% (95% CI 0.25, 8.73) at 6 months and by 7.03% (95% CI 4.37, 9.7) at 12 months. Similarly, RTX improved DLCO by 3.47% (95% CI 0.99, 5.96) at 6 months and 4.08% (95% CI 1.51, 6.65) at 12 months. In the two studies comparing RTX with other immunosuppressants, improvement of FVC by 6 months in the RTX group was 1.03% (95% CI 0.11, 1.94) greater than controls. At the 12 month follow-up, RTX treatment was similar to controls in terms of both FVC and DLCO. Patients treated with RTX had a lower chance of developing infections compared with controls [odds ratio 0.256 (95% CI 0.104, 0.626), I2 = 0%, P = 0.47). Conclusions Treatment with RTX in SSc-ILD was associated with a significant improvement of both FVC and DLCO during the first year of treatment. RTX use was associated with lower infectious adverse events.